Preparation method of IRAK4 protein and fusion protein adopted by same

By setting the fusion design of GST and Strep II tags on IRAK4 proteins, the problem of low purity and activity of IRAK4 proteins in the prior art is solved, and efficient protein expression and purification are achieved, improving the stability and purity of the protein.

CN118909142APending Publication Date: 2024-11-08ICE BIOSCI INC
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411077747.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing IRAK4 protein is not purified and has low activity and low yield after purification during the production process, making it difficult to effectively prepare efficient recombinant proteins.

Method used

The fusion protein design using the N-terminal to C-terminal setting of the GST tag and the Strep II tag was improved by combining the solid support of these tags for parenting and purification.

Benefits of technology

It effectively reduces the degradation of proteins during expression, improves the activity and purity of IRAK4 protein, and achieves efficient purification and improves the stability of proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909142A_ABST
    Figure CN118909142A_ABST
Patent Text Reader

Abstract

The invention generally relates to the field of molecular biology, in particular to a preparation method of IRAK4 protein and fusion protein adopted by the IRAK4 protein. The fusion protein sequentially comprises a GST label, an IRAK4 protein as shown in SEQ ID NO: 1 and a Strep II label from the N end to the C end. The invention accidentally finds that a GST tag and a Strep II tag are respectively arranged at the N end and the C end of the recombinant IRAK4 protein, so that the protein degradation in the expression process can be effectively reduced, and the activity of the IRAK4 protein can be improved. In addition, the double tags provide the possibility of two times of affinity purification for the purification process, impurities generated by protein degradation can be further removed, and the protein purity is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to the field of molecular biology, and in particular, to a method for preparing an IRAK4 protein and a fusion protein used therein. Background Art

[0002] Interleukin-1 receptor-associated kinase4 (IRAK-4) is a serine-threonine kinase expressed in lymphocytes and innate immune cells. It is involved in the regulation of TLR / IL-1R-mediated signaling pathways. It activates the expression of various downstream immune response-related genes by binding to myeloid differentiation factor 88 (MyD88) to form the Myddosome complex, which plays a critical role in the initiation of the human body's innate immune response against exogenous pathogens.

[0003] IRAK4 has been identified as a potential therapeutic target for a variety of diseases, including hematological malignancies and inflammatory skin diseases. Inhibition of IRAK4 activity has been shown to improve the therapeutic effects of diseases such as alcohol-induced liver damage and rheumatoid arthritis. Therefore, targeted inhibition of IRAK4 activity through methods such as kinase inhibitors or protein degradation is expected to treat a series of diseases characterized by dysregulated inflammatory responses and abnormal immune activation. Recombinant IRAK4 protein serves as a key raw material for high-throughput screening to help identify and optimize small molecule inhibitors of IRAK4 or other types of drug candidates in order to develop new therapeutic strategies.

[0004] The main problem with current IRAK4 protein production is that the protein obtained after purification is not of high purity and has low specific activity, and the protein yield obtained by certain purification methods is low. Summary of the invention

[0005] According to a first aspect of the present invention, a fusion protein is provided, which comprises, from the N-terminus to the C-terminus, a GST tag, an IRAK4 protein shown in SEQ ID NO: 1, and a Strep II tag.

[0006] According to another aspect of the present invention, an isolated nucleic acid is provided, which encodes the fusion protein as described above.

[0007] According to another aspect of the present invention, a vector is provided, which comprises the nucleic acid as described above.

[0008] According to another aspect of the present invention, a host cell is provided, comprising the nucleic acid as described above or the vector as described above.

[0009] According to another aspect of the present invention, a method for preparing IRAK4 protein is provided, comprising: a) culturing the host cell as described above to express the fusion protein; b) disrupting host cells to obtain a liquid composition containing the fusion protein; c) separating the fusion protein from the liquid phase composition using a solid support bound to a GST tag and / or a Strep II tag.

[0010] Beneficial effects of the present invention: The present invention unexpectedly found that setting a GST tag and a Strep II tag at the N-terminus and C-terminus of the recombinant IRAK4 protein respectively can effectively reduce protein degradation during the expression process and obtain improved IRAK4 protein activity. In addition, the double tag provides the possibility of two affinity purifications in the purification process, which can further remove impurities generated by protein degradation and improve protein purity. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0012] Figure 1 A schematic diagram of the IRAK4 protein purification flow path provided by one embodiment of the present invention; Figure 2 This is a graph showing the results of SDS-PAGE identification of IRAK4 protein purity provided in one embodiment of the present invention; Figure 3 A chromatographic result diagram of SEC-HPLC identification of IRAK4 protein provided in one embodiment of the present invention; Figure 4 A diagram showing the enzyme concentration titration result of the ADP-Glo ​​method activity analysis of IRAK4 protein provided in one embodiment of the present invention; Figure 5 Comparison of protein degradation of IRAK4 proteins labeled with N-GST and N-GST / C-Strep II; Figure 6 The purity test results of SDS-PAGE protein expressed and purified by GST-CDC25A-Strep II using the same technical scheme as the present invention; Figure 7The purity test result of SDS-PAGE protein expressed and purified by GST-CDC25B-Strep II is shown in FIG. DETAILED DESCRIPTION

[0013] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.

[0014] Unless otherwise indicated, the meaning of all terms (including technical and scientific terms) used to disclose the present invention is the same as that commonly understood by those of ordinary skill in the art to which the present invention belongs. By way of further guidance, the following definitions are used to better understand the teachings of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0015] In the present disclosure, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology and laboratory operation procedures used herein are terms and routine procedures widely used in the corresponding fields. At the same time, in order to better understand the present disclosure, the definitions and explanations of the relevant terms are provided below.

[0016] The terms "and / or", "or / and", and "and / or" used herein include any one of two or more related listed items, and also include any and all combinations of related listed items, wherein the any and all combinations include any combination of two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in the present invention, the technical solution undoubtedly includes technical solutions connected by "logical and", and undoubtedly includes technical solutions connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").

[0017] As used herein, the terms "comprising", "including" and "comprising" are synonymous and are inclusive or open-ended and do not exclude additional, unrecited members, elements or method steps.

[0018] Numerical ranges expressed as endpoints herein include all numbers and fractions subsumed within the range, as well as the recited endpoints.

[0019] The present invention relates to concentration values, and the meaning includes fluctuations within a certain range. For example, it can fluctuate within a corresponding precision range. For example, 2%, it is allowed to fluctuate within ±0.1%. For values ​​that are large or do not require too fine control, it is also allowed to have a greater fluctuation. For example, 100mM, it is allowed to fluctuate within the range of ±1%, ±2%, ±5%, etc. Involving molecular weight, it is allowed to have a fluctuation of ±10%.

[0020] As used herein, the singular articles "a," "an," and "the" include plural referents unless otherwise indicated.

[0021] In the present invention, descriptions such as "plurality" and "multiple" refer to quantities greater than or equal to 2 unless otherwise specified.

[0022] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0023] In the present invention, "preferably", "better", "more preferably", and "suitably" are only used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute a limitation on the scope of protection of the present invention. In the present invention, "optionally", "optional", and "optional" refer to being optional, that is, any one of the two parallel schemes of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent of each other.

[0024] Nucleic Acids The terms "nucleic acid molecule", "polynucleotide sequence" and "nucleotide sequence" used interchangeably in this specification refer to the precise sequence of modified or unmodified nucleotides, which defines a fragment or region of a nucleic acid, contains or does not contain non-natural nucleotides, and is double-stranded DNA or RNA, single-stranded DNA or RNA, or a transcription product of said DNA.

[0025] As used in the present invention, nucleic acids include, as non-limiting examples, all nucleic acid sequences obtained by any means available in the art, including, as non-limiting examples, recombinant means, i.e., cloning nucleic acid sequences from a recombinant library or a cell genome using common cloning techniques and PCR, etc., as well as synthetic means.

[0026] It should also be included here that the present invention does not relate to nucleotide sequences in their natural chromosomal environment, i.e. in a natural state. The sequences of the present invention have been isolated and / or purified, i.e. they have been sampled directly or indirectly, e.g. by copying, and their environment has been at least partially modified. Thus, isolated nucleic acids obtained by recombinant genetics, e.g. with the aid of host cells or obtained by chemical synthesis should also be mentioned here.

[0027] Unless otherwise specified, the term nucleotide sequence includes its complement. Thus, a nucleic acid having a specific sequence should be understood to include a nucleic acid having its complementary strand with its complementary sequence. "Complementary" should be understood to mean that the two can hybridize under stringent conditions. As used herein, the term "stringent conditions" refers to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) the addition of a denaturing agent during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 50%, preferably 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, or 90% or more, and more preferably 95% or more.

[0028] As used herein, unless otherwise specified, the term "fusion protein" refers to a protein obtained by fusion of an IRAK4 protein with an N-terminal GST tag and a C-terminal StrepII tag. The sequence of the IRAK4 protein in the fusion protein may be as shown in SEQ ID NO: 1, or a sequence having at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% sequence identity with SEQ ID NO: 1.

[0029] All documents mentioned in the present invention are cited as references in the present invention, just as each document is cited as a reference separately. Unless they conflict with the invention purpose and / or technical solution of the present invention, the cited documents involved in the present invention are cited with all contents and all purposes. When the present invention involves cited documents, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the present invention involves cited documents, the examples and preferred embodiments of the cited relevant technical features can also be incorporated into the present invention as references, but are limited to the ability to implement the present invention. It should be understood that when the cited content conflicts with the description in the present invention, the present invention shall prevail or be modified adaptively according to the description of the present invention.

[0030] The first aspect of the present invention relates to a fusion protein, which comprises, from the N-terminus to the C-terminus, a GST tag, an IRAK4 protein shown in SEQ ID NO: 1, and a Strep II tag.

[0031] The IRAK4 protein of the present invention may be: a protein or polypeptide encoded by the sequence shown in SEQ ID NO: 1, a homologous sequence having similar kinase function to the protein or polypeptide (for example, the homologous sequence can be obtained through a database or comparison software known in the art), a variant or modified form thereof. For example, the serine or threonine kinase may be selected from: (a) an amino acid sequence encoded by the sequence shown in SEQ ID NO: 1; (b) a protein or polypeptide derived from (a) that has proteolytic activity after substitution, deletion or addition of one or more amino acids in the amino acid sequence defined in (a); or (c) other amino acid sequences having IRAK4 enzymatic activity, such as a homologous sequence of the sequence encoded by SEQ ID NO: 1.

[0032] Variants of the proteins or polypeptides of the present invention include (but are not limited to): deletion, insertion and / or substitution of one or more (usually 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10, for example 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acids, and addition of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and / or N-terminus.

[0033] Variant forms of the protein also include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by sequences that can hybridize with serine and threonine kinase coding sequences under high or low stringency conditions, etc.

[0034] The second aspect of the present invention relates to an isolated nucleic acid encoding the fusion protein described in the first aspect.

[0035] An "isolated" nucleic acid is a nucleic acid molecule that has been identified and separated from at least one nucleic acid-impurity with which it is normally associated in the natural source of the nuclease nucleic acid. An isolated nucleic acid is other than in the form or assembly in which it is found in nature.

[0036] In some embodiments, the nucleotide sequence encoding the IRAK4 protein in the isolated nucleic acid is as shown in SEQ ID NO:2.

[0037] Compared with the wild type, the codon-optimized nucleic acids shown in SEQ ID NO: 2 all showed increased IRAK4 protein production levels; in addition, the codon-optimized nucleic acid of the present invention having the nucleotide sequence of SEQ ID NO: 2 unexpectedly showed the best results, especially when combined with the GST tag and the Strep II tag to obtain ideal protein stability and activity.

[0038] The third aspect of the present invention relates to a vector comprising the nucleic acid described in the second aspect.

[0039] The term "vector" refers to a nucleic acid carrier into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, and include but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phage or M13 phage and animal viruses. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomas (such as SV40), and insect baculoviruses.

[0040] In some embodiments, the vector further comprises one or more elements selected from the group consisting of: i) Promoter; ii) signal peptide coding sequence; iii) leader coding sequence; iv) terminator; v) marker genes; vi) Polyadenylation sequence.

[0041] In some embodiments, the basic backbone of the vector is derived from the pFastbac1 plasmid.

[0042] The fourth aspect of the present invention relates to a host cell, which comprises the nucleic acid described in the second aspect or the vector described in the third aspect.

[0043] The host cell can be a higher eukaryotic cell, such as an insect cell or a mammalian cell; a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell.

[0044] In some embodiments, the host cell is an insect cell.

[0045] In some preferred embodiments, the host cell is an Sf9 cell.

[0046] The fifth aspect of the present invention relates to a method for preparing IRAK4 protein. The nucleic acid / vector of the present invention can be used to express or produce recombinant protein by conventional recombinant DNA technology (Science, 1984; 224: 1431). Commonly used expression systems include Escherichia coli expression system, insect-baculovirus expression vector system (BEVS), mammalian cell expression system and yeast expression system. Those skilled in the art can select according to their needs.

[0047] Specifically, the method for preparing the IRAK4 protein comprises: a) culturing the host cell described in the fourth aspect to express the fusion protein; b) disrupting host cells to obtain a liquid composition containing the fusion protein; c) separating the fusion protein from the liquid phase composition using a solid support bound to a GST tag and / or a Strep II tag.

[0048] Comparing steps b) and c), if necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.

[0049] The phrase "solid support" refers to any solid surface including, but not limited to, any chip (e.g., a silica-based, glass-based or gold-based chip), a slide, a membrane, a bead, a solid particle [e.g., agarose, Sepharose, polystyrene or magnetic beads], a column (or column material), a test tube or a microtiter plate. Preferably, it is an affinity chromatography column.

[0050] In some embodiments, step c) is affinity chromatography.

[0051] In some embodiments, GST affinity chromatography and Strep II affinity chromatography are performed sequentially.

[0052] In comparison, the traditional method uses a one-step GST affinity chromatography purification technology that takes one day, and the resulting protein purity is less than 70%. SDS-PAGE results show the presence of degraded N-terminal bands and GST tag band impurities. The present invention preferably uses GST and Strep II dual affinity chromatography, which can effectively provide protein purity (up to more than 95%) and reduce the generation of impurities.

[0053] In some embodiments, the solid supports required for the GST affinity chromatography and the Strep II affinity chromatography are connected in series to a protein purification instrument, and the purification process of the two-step affinity chromatography is completed in one experiment.

[0054] In some embodiments, the GST affinity chromatography uses a GSTrap column.

[0055] In some embodiments, the Strep II affinity chromatography uses a PreCap Streptactin column.

[0056] The protein purification instrument integrates two-step affinity chromatography into one operation step, so that two-step affinity chromatography can be completed automatically in one experiment, which simplifies the operation, improves the efficiency of the process, makes the process easy to standardize, and reduces the interference of human and environmental factors. In addition, the process can shorten the purification process to one day, shortening the preparation cycle.

[0057] The embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present invention, and can also be based on the experimental manual or normal conditions in this area, and can also be based on other experimental methods known in the art, or according to the conditions recommended by the manufacturer.

[0058] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0059] Example 1 1) Related genes In the present invention, a fusion protein vector is constructed and expressed.

[0060] The structure of the fusion protein molecule is: GST-IRAK4-Strep II.

[0061] The amino acid sequence of the IRAK4 protein used is shown in SEQ ID NO:1.

[0062] The nucleic acid corresponding to the above amino acid sequence was codon-optimized for the host cell Sf9 cell, and the obtained nucleotide sequence was shown in SEQ ID NO:2.

[0063] 2) Construction of plasmid The gene shown in SEQ ID NO: 2 was cloned into the pFastbac1 plasmid by homologous recombination and named pFastbac1-IRAK4.

[0064] Example 2—Expression of IRAK4 protein in insect cells 1) Plasmid transformation and blue-white screening The pFastbac1-IRAK4 plasmid was transformed into DH10Bac competent cells. The transformed bacterial solution was diluted three times (10 -1 -10 -3 ) and then spread onto solid medium (50 µg / ml kanamycin, 7 µg / ml gentamicin, 10 µg / ml tetracycline, 100 µg / ml X-gal and 40 µg / ml IPTG) and cultured at 37°C for two days before blue-white screening.

[0065] 2) Extraction and verification of recombinant bacmid Pick the white spot colonies and culture them overnight in 5 ml LB medium (1:1000 with 50 mg / ml Kana, 10 mg / ml tetracycline, and 7 mg / ml gentamicin).

[0066] On the next day, take 1 ml of overnight bacterial culture and extract the bacmid using a commercial plasmid extraction kit.

[0067] Verification of recombinant bacmids: Use M13F / M13R primers to amplify the gene fragment according to the PCR method described in the Thermo Fisher Insect Cell Expression Manual and run 1% agarose to verify whether the PCR fragment size is correct.

[0068] 3) Transfection of recombinant bacmid into insect Sf9 cells 0.9 × 10 cells were seeded per well in a six-well plate. 6 Sf9 cells.

[0069] 1µg of recombinant bacmid and 8µL of cellfect II were mixed and added to the culture medium, and the culture was continued at 27°C for 5 days.

[0070] 4) Amplification of P2 virus The P1 virus was collected and diluted at a ratio of 1:1000 to infect 100 ml of 1×10 6 Sf9 cells were cultured at 27°C for 3 days.

[0071] 5) Large-scale protein expression and collection of expressing cells Collect the P2 virus and add P2 virus to infect 1000 ml of 1×10 6 Sf9 cells were cultured at 27°C for 39 hours.

[0072] The expressing cells were collected and stored in a -80°C refrigerator.

[0073] Example 3 - Protein Purification 1. Resuspension and disruption of expressing cells Resuspend the cell pellet in a ratio of 10 ml lysis buffer (20 mM Tris, pH 7.5, 300 mM NaCl, 1 mM DTT, 1 mM mixed protein inhibitor) per 1 g of expressed cells and mix well on a magnetic stirrer. The resuspended cell suspension was broken three times on a high-pressure homogenizer at 4 °C and a pressure of ~300 bar.

[0074] 2. Clarification of the Broken Liquid The resulting cell lysate was centrifuged at 48,000×g and 4° C. for 60 minutes in a high-speed centrifuge. The precipitate was discarded and the supernatant was collected.

[0075] 3. Purification by GST and Strep II affinity chromatography 1) Column connection Connect the GST prepacked column to the injection valve position of the Autopure, and connect the Strep II prepacked column to the sample valve position of the Autopure.

[0076] Schematic diagram of IRAK4 protein purification flow path Figure 1 shown.

[0077] 2) Buffer and configuration A1 pump was placed with A1 buffer: 20 mM Tris, pH7.5, 300 mM NaCl, 1 mM DTT; A2 pump is used to place A2 buffer: sample to be chromatographed; B1 pump placed in B1 buffer: 50 mM Tris, pH7.5, 150 mM NaCl, 20 mM GSH, 1 mM DTT; The B2 pump is filled with B2 buffer: 50 mM Tris, pH7.5, 150 mM NaCl, 1 mM DTT, 5 mM D-biotin.

[0078] 3) Edit the program in the Autopure method editor to implement the following process:

[0079] The program was run at 4°C to obtain recombinant IRAK4 protein.

[0080] Example 4 - Quality Identification 1) Use SDS-PAGE (4%-12% density gradient gel) to identify the purity of the protein. Figure 2 As shown. Further measurement showed that the purity of IRAK4 protein sample was greater than 95%.

[0081] 2) OD280nm to measure protein concentration Using a protein-free buffer as a blank control, the OD280 nm absorbance of the IRAK4 protein solution was detected and divided by the extinction coefficient Abs0.1% (g / L): 1.063 to obtain the actual concentration:

[0082] 3) Run SEC-HPLC, the results are as follows: The experimental conditions are shown in the following table:

[0083] The experimental chromatographic results are as follows Figure 3 shown.

[0084] It can be seen that IRAK4 protein exists in the form of GST dimer in the solution.

[0085] 4) ADP-Glo ​​activity analysis Operation process: a) Use Echo to transfer 50 nL DMSO to the reaction plate, add 2.5 μL of serially diluted IRAK4 protein, and incubate at 25°C for 10 min.

[0086] b) Add 2.5 μL of a mixture of 20 μM ATP and 0.2 mg / ml Myelin Basic Protein substrate to each well and react for 60 min.

[0087] c) Add 4 μL ADP-Glo ​​Reagent to each well and react for 40 min.

[0088] d) Add 8 μL ADP-Glo ​​Detection to each well and react for 40 min.

[0089] Luminescence signal values ​​were read using a BMG instrument.

[0090] Activity assay results Figure 4 As shown in the figure, IRAK4 protein has a large window at a concentration below 1 nM and shows a linear relationship, indicating that the sample has high activity.

[0091] Comparative Example 1. C-terminal Strep II improves the stability of IRAK4 protein expression in vitro It can be seen from the above examples that the present invention can effectively improve the purity and protein activity of IRAK4 by constructing the GST-IRAK4-Strep II fusion protein using double tags, and it is unexpectedly found that the improvement exceeds the inventor's expectations.

[0092] To further verify the effect of Strep II tag on IRAK4 protein expression, the inventors used traditional methods to construct IRAK4 protein containing only GST tag at N-terminus as control. The sequence used in the control sample and the related experimental methods are the same as those in Examples 1 to 4, the only difference being that the fusion protein structure of the control sample is different from that of the examples.

[0093] The results are as follows Figure 5 As shown, the control sample (N-GST) and the double-tag fusion protein sample (N-GST / C-Strep II) used in the present invention are compared. After one-step GST affinity chromatography purification, the control sample has a significantly higher content of IRAK4 protein degradation than the double-tag fusion protein sample. This shows that the improvement of the purity of IRAK4 in the present invention is not only due to the improvement brought by Strep II column purification. The introduction of Strep II tag itself can improve the structure of fusion protein, increase the stability of IRAK4 protein, and reduce protein degradation.

[0094] 2. GST-IRAK4-Strep II specifically improves the expression of IRAK4 protein Furthermore, to verify whether the improvement of protein stability by Strep II tag is universal, the inventors applied the expression model to the expression of CDC25A (amino acid sequence as shown in SEQ ID NO: 3) and CDC25B (amino acid sequence as shown in SEQ ID NO: 4) proteins.

[0095] The relevant experimental methods used for GST-CDC25A-Strep II and GST-CDC25B-Strep II are the same as those shown in Examples 1 to 4, with the only difference being that the target protein sequence is different from that in the examples.

[0096] Related results such as Figure 6 and Figure 7 As shown, it can be clearly seen that the same technical means were used to obtain relatively pure proteins for CDC25A and CDC25B.

[0097] This indicates that the improvement of protein stability by the Strep II tag is protein-specific rather than a universal property.

[0098] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims, and the description and drawings can be used to interpret the content of the claims.

Claims

1. A fusion protein, characterized in that: From the N-terminus to the C-terminus, it includes a GST tag, the IRAK4 protein shown in SEQ ID NO: 1, and a Strep II tag.

2. An isolated nucleic acid, characterized in that Encodes the fusion protein of claim 1.

3. The isolated nucleic acid according to claim 2, characterized in that The nucleotide sequence encoding IRAK4 protein is shown in SEQ ID NO:

2.

4. A carrier, characterized in that Comprising the nucleic acid according to claim 2 or 3.

5. The carrier according to claim 4, characterized in that The vector further comprises one or more elements selected from the group consisting of: i) Promoter; ii) signal peptide coding sequence; iii) leader coding sequence; iv) terminator; v) marker genes; vi) Polyadenylation sequence.

6. The carrier according to claim 4, characterized in that The basic backbone of the vector is derived from the pFastbac1 plasmid.

7. A host cell, characterized in that It comprises the nucleic acid according to claim 2 or 3 or the vector according to any one of claims 4 to 6.

8. The host cell according to claim 7, characterized in that These are Sf9 cells.

9. A method for preparing IRAK4 protein, characterized in that: include: a) culturing the host cell according to claim 7 or 8 to express the fusion protein; b) disrupting host cells to obtain a liquid composition containing the fusion protein; c) separating the fusion protein from the liquid phase composition using a solid support bound to a GST tag and / or a Strep II tag.

10. The preparation method according to claim 9, characterized in that Step c) is affinity chromatography; GST affinity chromatography and Strep II affinity chromatography are performed sequentially; The solid supports required for the GST affinity chromatography and the Strep II affinity chromatography are connected in series to a protein purifier, and the purification process of the two-step affinity chromatography is completed in one experiment.

Citation Information

Patent Citations

  • Long-acting artesunate drug for preventing schistosome infection and preparation method thereof

    CN103405779A

  • Multifunctional tag fusion protein, expression method and applications thereof

    CN106543272A

  • Method for obtaining target protein, fusion protein, carrier and application

    CN115992159A

  • Method for measuring IRAK4 expression quantity

    CN116818877A

  • Composition for functional regulation of t cell receptor and method for screening the same

    JP2006290848A